Boxer Capital Management, LLC holds a focused book of 54 stocks worth $761.7M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Vaxcyte Inc and trimmed Inovio Pharmaceuticals Inc. Their largest long position is Tango Therapeutics Inc at 30% of the equity book. Cloning the disclosed picks since 2025 would be +297% (+160.0%/yr). That is a simulation of the disclosed long book, not audited returns.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2018299/holdings"
Use Arkolith to show Boxer Capital Management, LLC's latest holdings, largest changes, and filing provenance.
Following at the filing date actually beat the quarter-end book by 46.0 points over this window.
Growth of $10,000 cloning Boxer Capital Management, LLC's disclosed long 13F book, rebalanced on each filing date (so it reflects the ~45-day reporting lag, no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
95% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Boxer Capital Management, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| UBS Group AG | 53 / 54 | $2.4B |
| GEODE CAPITAL MANAGEMENT, LLC | 52 / 54 | $2.6B |
| MORGAN STANLEY | 52 / 54 | $2.0B |
| BlackRock, Inc. | 51 / 54 | $10.6B |
| STATE STREET CORP | 51 / 54 | $4.1B |
| GOLDMAN SACHS GROUP INC | 50 / 54 | $1.9B |
| BNP PARIBAS FINANCIAL MARKETS | 50 / 54 | $395.9M |
| BARCLAYS PLC | 50 / 54 | $172.3M |
Ranked by how many of Boxer Capital Management, LLC's top 54 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Tango Therapeutics Inc COM | $227.5M | 10.88M | 29.9% | —Held | |
| 2 | Kodiak Sciences Inc COM | $51.9M | 1.36M | 6.8% | ▲+20% Added · +225K sh | |
| 3 | Revolution Medicines Inc COM | $48.6M | 500.0K | 6.4% | ▲+25% Added · +100K sh | |
| 4 | Kymera Therapeutics Inc COM | $27.4M | 329.1K | 3.6% | —Held | |
| 5 | Celcuity Inc COM | $25.7M | 225.0K | 3.4% | —Held | |
| 6 | Surrozen Inc COM NEW | $22.3M | 766.3K | 2.9% | ▲+84% Added · +350K sh | |
| 7 | Abivax Sa SPONSORED ADS | $22.3M | 200.0K | 2.9% | ▲+60% Added · +75K sh | |
| 8 | Terns Pharmaceuticals Inc COM | $19.8M | 375.0K | 2.6% | —Held | |
| 9 | Vaxcyte Inc COM | $18.9M | 325.0K | 2.5% | ▲New New position | |
| 10 | Capricor Therapeutics Inc COM NEW | $17.9M | 590.0K | 2.4% | ▲+82% Added · +265K sh | |
| 11 | Protagonist Therapeutics Inc COM | $17.9M | 170.0K | 2.4% | —Held | |
| 12 | Vir Biotechnology Inc COM | $16.7M | 1.87M | 2.2% | ▲+199% Added · +1.2M sh | |
| 13 | Corvus Pharmaceuticals Inc COM | $16.1M | 1.10M | 2.1% | ▲New New position | |
| 14 | Praxis Precision Medicines I COM NEW | $15.0M | 46.5K | 2.0% | —Held | |
| 15 | PTC Therapeutics Inc COM | $13.6M | 200.0K | 1.8% | —Held | |
| 16 | Precigen Inc COM | $13.5M | 3.50M | 1.8% | ▲+155% Added · +2.1M sh | |
| 17 | Definium Therapeutics Inc COM SHS | $11.3M | 598.5K | 1.5% | ▲New New position | |
| 18 | Amylyx Pharmaceuticals Inc COM | $11.1M | 800.0K | 1.5% | —Held | |
| 19 | Uniqure NV SHS | $10.8M | 662.0K | 1.4% | ▲+128% Added · +372K sh | |
| 20 | Opus Genetics Inc COM | $10.2M | 2.25M | 1.3% | ▲New New position | |
| 21 | Corcept Therapeutics Inc COM | $10.1M | 250.0K | 1.3% | ▲New New position | |
| 22 | Urogen Pharma Ltd COM | $9.0M | 500.0K | 1.2% | —Held | |
| 23 | Replimune Group Inc COM | $9.0M | 1.18M | 1.2% | ▲+57% Added · +425K sh | |
| 24 | Cogent Biosciences Inc COM | $8.7M | 225.0K | 1.1% | —Held | |
| 25 | Palisade Bio Inc COM | $8.4M | 4.80M | 1.1% | —Held | |
| 26 | Crescent Biopharma Inc. COM | $8.3M | 453.7K | 1.1% | ▲New New position | |
| 27 | Soleno Therapeutics Inc COM | $6.7M | 200.0K | 0.9% | ▲New New position | |
| 28 | Allogene Therapeutics Inc COM | $6.6M | 2.73M | 0.9% | ▲New New position | |
| 29 | Cytokinetics Inc COM NEW | $6.6M | 100.0K | 0.9% | —Held | |
| 30 | Contineum Therapeutics Inc CL A | $6.5M | 494.0K | 0.8% | —Held | |
| 31 | Apogee Therapeutics Inc COM | $5.9M | 70.0K | 0.8% | —Held | |
| 32 | Relmada Therapeutics Inc COM | $5.9M | 842.1K | 0.8% | ▲New New position | |
| 33 | Zura Bio Ltd CLASS A ORD SHS | $5.4M | 900.0K | 0.7% | ▲18× Added · +850K sh | |
| 34 | Moonlake Immunotherapeutics CLASS A ORD | $5.1M | 275.0K | 0.7% | —Held | |
| 35 | Avalo Therapeutics Inc COM NEW | $4.5M | 300.0K | 0.6% | ▲+9.1% Added · +25K sh | |
| 36 | Inovio Pharmaceuticals Inc COM SHS | $4.1M | 2.37M | 0.5% | ▼−2.1% Reduced · −50K sh | |
| 37 | Structure Therapeutics Inc SPONSORED ADS | $3.6M | 75.0K | 0.5% | —Held | |
| 38 | Sarepta Therapeutics Inc COM | $3.3M | 150.0K | 0.4% | —Held | |
| 39 | Cybin Inc COM NEW | $3.1M | 640.0K | 0.4% | ▼−10% Reduced · −75K sh | |
| 40 | Ocular Therapeutix Inc COM | $3.0M | 350.0K | 0.4% | ▲New New position | |
| 41 | An2 Therapeutics Inc COM | $2.6M | 749.0K | 0.3% | ▲New New position | |
| 42 | Clene Inc COM NEW | $2.4M | 477.5K | 0.3% | ▲+139% Added · +278K sh | |
| 43 | Oric Pharmaceuticals Inc COM | $2.2M | 176.5K | 0.3% | ▲New New position | |
| 44 | Solid Biosciences Inc COM NEW | $2.2M | 300.0K | 0.3% | —Held | |
| 45 | Invivyd Inc COM | $1.9M | 1.50M | 0.3% | —Held | |
| 46 | LB Pharmaceuticals Inc COM SHS | $1.7M | 70.0K | 0.2% | —Held | |
| 47 | Karyopharm Therapeutics Inc COM NEW | $1.7M | 302.5K | 0.2% | ▲+20% Added · +50K sh | |
| 48 | Nurix Therapeutics Inc COM | $1.6M | 100.0K | 0.2% | —Held | |
| 49 | Upstream Bio Inc COM | $1.4M | 150.0K | 0.2% | —Held | |
| 50 | Milestone Pharmaceuticals In COM | $793K | 666.7K | 0.1% | —Held |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 54 | $761.7M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 45 | $456.9M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Feb 17, 2026 | 34 | $313.7M | 13F-HR/A |
| Q2 2025 | Jun 30, 2025 | Feb 17, 2026 | 20 | $198.7M | 13F-HR/A |
| Q1 2025 | Mar 31, 2025 | Feb 17, 2026 | 28 | $332.5M | 13F-HR/A |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 60 | $1.2B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.